Search research articles
Contact Us
Filters
Showing results (151-160 of 169) with videos related to
Page
of 17
Sort By:
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
The New England Journal of Medicine
|
April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz, Alessandra Mangia, David Wyles, et al.
The Lancet. Infectious Diseases
|
March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Journal of Hepatology
|
March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
JAMA
|
February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection
Anu Osinusi, Kerry Townsend, Anita Kohli, et al.
The New England Journal of Medicine
|
April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
Nezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine
|
April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Hepatology (Baltimore, Md.)
|
February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
Amaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Journal of Hepatology
|
May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Kosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 169) with videos related to
Sort By:
Page
of 17
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
The New England Journal of Medicine
|
April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz, Alessandra Mangia, David Wyles, et al.
The Lancet. Infectious Diseases
|
March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Journal of Hepatology
|
March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
JAMA
|
February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection
Anu Osinusi, Kerry Townsend, Anita Kohli, et al.
The New England Journal of Medicine
|
April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
Nezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine
|
April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Kris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Hepatology (Baltimore, Md.)
|
February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
Amaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Journal of Hepatology
|
May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Kosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Page
of 17